Did you mean bitopertin of ro 493838 of r 168 of ビトペルチン?
Displaying drugs 626 - 650 of 9627 in total
Tildrakizumab
Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis .
The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy...
Approved
Investigational
Matched Description: … The approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every ... A study was performed on the pharmacokinetics of this drug on various ethnicities. ... high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of …
Ethotoin
Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread...
Approved
Matched Description: … The mechanism of action is probably very similar to that of phenytoin. ... seizure activity rather than to abolish the primary focus of seizure discharges. ... drug appears to stabilize rather than to raise the normal seizure threshold, and to prevent the spread of …
Osimertinib
Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing...
Approved
Matched Description: … due to the presence of specific activating EGFR mutations within the tumour cells. ... [A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC ... Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs …
Givosiran
Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic...
Approved
Investigational
Matched Description: … patisiran]), a new class of drugs promising an important and exciting step forward in the treatment of ... Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of ... [L10202] Givosiran represents an important step forward in the treatment of acute hepatic porphyria as …
Icodextrin
Icodextrin is an iso-osmotic peritoneal dialysis solution containing glucose polymers. It is used primarily for ambulatory peritoneal dialysis (CAPD) of diabetic patients and automated peritoneal dialysis (APD) for patients with end-stage renal disease. It is injected as a solution into the peritoneal cavity. The drug is absorbed via convective transport...
Approved
Investigational
Matched Description: … It is used primarily for ambulatory peritoneal dialysis (CAPD) of diabetic patients and automated peritoneal …
Lifitegrast
Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process. The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. It has...
Approved
Matched Description: … onset of action and well tolerated profile in both local and systemic setting [A18805]. ... Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome) ... It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast …
Cabotegravir
Cabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, rilpivirine.[A227668,L31188,L31193] Early research into cabotegravir showed it had lower oral bioavailability than dolutegravir, which resulted in the development of long acting monthly intramuscular injection formulation for cabotegravir.[A227668,L31193]
Cabotegravir was granted FDA approval on...
Approved
Investigational
Matched Description: … showed it had lower oral bioavailability than [dolutegravir],[A227668] which resulted in the development of …
Satralizumab
Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to tocilizumab, which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disorder of the central...
Approved
Matched Description: … permeability of the blood-brain barrier, which allows for the passage of pro-inflammatory mediators ... This novel mechanism effectively increases the duration of action of satralizumab, as it allows for single ... autoimmune inflammatory disorder of the central nervous system (CNS) involving demyelinating lesions …
Fosdenopterin
Molybdenum cofactor deficiency (MoCD) is an exceptionally rare autosomal recessive disorder resulting in a deficiency of three molybdenum-dependent enzymes: sulfite oxidase (SOX), xanthine dehydrogenase, and aldehyde oxidase. Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites resulting from a lack of SOX activity.[A230088,L32163]...
Approved
Matched Description: … resulting from a lack of SOX activity. ... of this debilitating disorder. ... The most common subtype of MoCD, type A, involves mutations in _MOCS1_ wherein the first step of molybdenum …
Enmetazobactam
Enmetazobactam is a penicillanic acid sulfone extended-spectrum beta (β)-lactamase (ESBL) inhibitor. Because ESBL enzymes can hydrolyze important antibiotics such as penicillins, broad-spectrum cephalosporins and monobactams, ESBL-producing bacteria poses challenges in the treatment of serious infections. The combination product of enmetazobactam and cefepime was first approved by the FDA on February...
Approved
Matched Description: … on February 23, 2024, for the treatment of complicated urinary tract infections. ... [A263276]
The combination product of enmetazobactam and [cefepime] was first approved by the FDA ... broad-spectrum cephalosporins and monobactams, ESBL-producing bacteria poses challenges in the treatment of …
Mirabegron
Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as solifenacin and darifenacin, it lacks significant antimuscarinic activity, which is...
Approved
Matched Description: … these medications and their broad range of adverse effects. ... the bladder in the treatment of urinary frequency and incontinence. ... Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of …
Exenatide
Exenatide is a glucagon-like peptide-1 (GLP-1) analog . It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control . Exenatide was given FDA approval on April 28, 2005 . It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand...
Approved
Investigational
Matched Description: … [L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension …
Tezacaftor
Tezacaftor is a drug of the cystic fibrosis transmembrane conductance regulator (CFTR) potentiator class. It was developed by Vertex Pharmaceuticals and FDA approved in combination with ivacaftor to manage cystic fibrosis. This drug was approved by the FDA on February 12, 2018. Cystic Fibrosis is an autosomal recessive disorder caused...
Approved
Investigational
Matched Description: … CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, ... Tezacaftor is a drug of the cystic fibrosis transmembrane conductance regulator (CFTR) potentiator class ... Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and …
Misoprostol
Misoprostol is a prostaglandin analog used to reduce the risk of NSAID related ulcers, manage miscarriages, prevent post partum hemorrhage, and also for first trimester abortions.[L7616,L7619,A181589,A181583,A181697] The stimulation of prostaglandin receptors in the stomach reduces gastric acid secretion, while stimulating these receptors in the uterus and cervix can increase the...
Approved
Matched Description: … Misoprostol is a prostaglandin analog used to reduce the risk of NSAID related ulcers, manage miscarriages ... [L7616,L7619,A181589,A181583,A181697] The stimulation of prostaglandin receptors in the stomach reduces ... while stimulating these receptors in the uterus and cervix can increase the strength and frequency of …
Betaxolol
A cardioselective beta-1-adrenergic antagonist with no partial agonist activity.
Approved
Investigational
Nintedanib
Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one...
Approved
Matched Description: … Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic ... [L8453] Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently ... one of only two disease-modifying therapies available and indicated for the condition (the other being …
Celiprolol
Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris. It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist. In 2010 a clinical trial has suggested a use for this medication in the prevention of...
Approved
Investigational
Matched Description: … rupture in which the layers of the vessel separate prior to complete failure of the artery wall). ... This study demonstrated decreased incidence of arterial rupture or dissection (a specific type of arterial ... of a rare inherited disease called vascular Ehlers–Danlos syndrome. …
Vericiguat
Vericiguat is a direct stimulator of soluble guanylate cyclase (sGC) used in the management of systolic heart failure to reduce mortality and hospitalizations. A key component of the NO-sGC-cGMP signaling pathway that helps to regulate the cardiovascular system, sGC enzymes are intracellular enzymes found in vascular smooth muscle cells (amongst...
Approved
Investigational
Matched Description: … Vericiguat is a direct stimulator of soluble guanylate cyclase (sGC) used in the management of systolic ... [L31153] A key component of the NO-sGC-cGMP signaling pathway that helps to regulate the cardiovascular ... enzymes found in vascular smooth muscle cells (amongst other cell types) that catalyze the synthesis of …
Tovorafenib
Tovorafenib is a selective type II RAF kinase inhibitor with anti-tumour activity. It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic therapy for the treatment of pediatric low-grade glioma, with BRAF rearrangements. BRAF oncogenic mutations in cancers drive dysregulated cell growth, proliferation,...
Approved
Investigational
Matched Description: … therapy for the treatment of pediatric low-grade glioma, with BRAF rearrangements. ... [A263597] It was granted accelerated approval by the FDA, making it the first FDA approval of a systemic …
Ethylhexyl methoxycrylene
Ethylhexyl methoxycrylene is a photostabilizer that preserves the effectiveness of UV filters by interacting with both the singlet and triplet states . It returns UV filters to their ground states without absorbing sunlight . It is used as a solvent for crystalline UV filters and is easily emulsified and suitable...
Approved
Experimental
Matched Description: … Ethylhexyl methoxycrylene is a photostabilizer that preserves the effectiveness of UV filters by interacting …
Dostarlimab
Dostarlimab is an IgG4 humanized monoclonal antibody targeted against the human programmed death receptor-1 (PD-1). PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the anti-tumor immune response that would typically attempt...
Approved
Investigational
Matched Description: … cancers, including those of the skin, lung, kidneys, and liver. ... [L45161] Dostarlimab-gxly was granted second accelerated approval for the treatment of solid tumours ... accelerated approval by the FDA - as GlaxoSmithKline's dostarlimab-gxly (Jemperli) - for the treatment of …
Human thrombin
Human thrombin is a sterile solution, pH 6.8-7.2, containing highly purified human thrombin for the activation of clotting. Thrombin is a highly specific serine protease encoded by the F2 gene that transforms soluble fibrinogen into insoluble fibrin. This transformation mimics the final coagulation cascade step which involves the clotting mass...
Approved
Matched Description: … thrombin is a sterile solution, pH 6.8-7.2, containing highly purified human thrombin for the activation of ... which involves the clotting mass that adheres to the wound surface and achieves hemostasis and sealing of ... Furthermore, human thrombin is manufactured by chromatographic purification of prothrombin from cryo-poor …
Dasatinib
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein...
Approved
Investigational
Matched Description: … pathogenesis of CML and 15-30% of ALL cases. ... Since dasatinib does not interact with some of the residues involved in those mutations, the use of this ... [A2226] The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186] …
Drotrecogin alfa
Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated...
Approved
Investigational
Withdrawn
Matched Description: … It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and …
Displaying drugs 626 - 650 of 9627 in total